The endTB consortium has completed endTB-Q, the first Phase 3 randomized controlled trial to exclusively enroll people with pre-extensively drug-resistant tuberculosis (pre-XDR-TB), a very hard-to-treat form of tuberculosis (TB). The trial, conducted by the endTB consortium (Médecins Sans Frontières, Partners In Health, and IRD), demonstrated that a shorter treatment strategy than the conventional treatment and comprised of a combination of four drugs—bedaquiline, clofazimine, delamanid, and linezolid (BCDL)—achieved high cure rates overall and especially good results in the population with non-severe cases of the TB disease. Preliminary results are being presented at the Union World Conference on Lung Health in Bali, Indonesia on November 13, 2024. 

Read the press release and more about the endTB-Q trial results here.